The anticoagulant dabigatran performed safely and effectively in a group of 938 unselected patients with atrial fibrillation, according to a German study presented at a meeting. Less than 2% of the patients experienced major cardiovascular events, and 1% experienced minor cardiovascular events. Bleeding complications were experienced by 14.9% of patients, but only 1.5% faced major bleeding, the study found.

Related Summaries